
    
      This study is an open-label, single-arm, single-center, phase 2 clinical trial. Eligible
      patients are with previously untreated gastric and gastroesophageal junction adenocarcinoma
      as defined by cT2-4 and/or cN+ without evidence of metastatic disease. Patients will receive
      3 cycles of 20 mg oral Lenvatinib daily plus 200 mg intravenous Pembrolizumab every 3 weeks
      as the neoadjuvant treatment followed by surgery, and then 3 cycles of Lenvatinib plus
      Pembrolizumab followed by 11 cycles of Pembrolizumab monotherapy as the adjuvant treatment.
    
  